Obesity Drug Pipeline Is 70% Incretin-Based: Review of 275 Clinical Trials | Research

The takeaway

Of 275 obesity drug trials registered over 5 years, 70% target the incretin pathway (GLP-1/GIP/glucagon), with most in Phase 2-3, raising concerns about mechanistic diversity and long-term safety data.

70% incretin-based
Of 275 registered obesity drug trials, nearly three-quarters target the GLP-1/GIP/glucagon pathway

What the researchers found

Incretin pathway modulators comprised 69.8% of 275 obesity drug trials (2019-2024), with 40.7% in Phase 2 and 31.3% in Phase 3. Early-stage innovation was limited at 3.3%, and drug repurposing accounted for 22.2%.

Why it matters

While incretin drugs are effective, relying on a single mechanism class for obesity treatment creates risks—if long-term safety issues emerge, few alternatives will be ready.

How the study worked

Systematic review of clinical trials registered on ClinicalTrials.gov from October 2019 to October 2024, analyzing pharmacological interventions for obesity across development stages.

What this study cannot tell us

Only covers ClinicalTrials.gov registrations; may miss some international trials. Pipeline snapshot from a specific time window. Cannot predict which candidates will succeed.

How to read the evidence

Systematic review of trial registrations — comprehensive landscape analysis but does not assess trial outcomes.

When this study was published

Published in 2025, analyzing the 2019-2024 trial landscape.

The bigger picture

The pharmaceutical pipeline for obesity has never been stronger, but its heavy reliance on incretin peptides creates a fragile ecosystem that needs diversification for sustainable, equitable obesity management.

Questions still open

What non-incretin mechanisms show the most promise for future obesity drugs?
Will the incretin dominance lead to cost and access problems if the pipeline lacks diversity?
Are there safety signals unique to long-term incretin use that may emerge?

Common questions

Are all new obesity drugs based on GLP-1?

Nearly — 70% of obesity drug trials from 2019-2024 target the incretin pathway (GLP-1, GIP, or glucagon receptors). While these drugs are effective, the field needs more diverse approaches as backup options.

What other types of obesity drugs are being developed?

The remaining 30% includes diverse targets like melanocortin receptors, mitochondrial uncouplers, gut microbiome modulators, and neurological appetite regulators, but these are less advanced in development.

Read the original research

Incretin Dominance and Emerging Mechanisms in Obesity Pharmacotherapy: Insights from 275 Registered Clinical Trials (2019-2024).

Therapeutic innovation & regulatory science, 60(1), 223-247

View on PubMed ↗Publisher’s paper ↗

Citation

Dos Santos Barbosa, Lucas Antônio; Almarie, Bassel; Moreira, Eduardo Luiz Gasnhar. (2026). Incretin Dominance and Emerging Mechanisms in Obesity Pharmacotherapy: Insights from 275 Registered Clinical Trials (2019-2024).. Therapeutic innovation & regulatory science, 60(1), 223-247. https://doi.org/10.1007/s43441-025-00875-y